Dr. Jones discusses clinical fracture incidence in mHSPC

In this podcast, Prof. Igor Tsaur (DE), chief editor of the UROONCO PCa editorial board talks with Dr. Craig Jones (GB),  from Salford Royal and Christie Hospitals, about his recent presentation at AUA2023, "Clinical fracture incidence in metastatic hormone-sensitive prostate cancer (mHSPC) and risk-reduction following addition of zoledronic acid to androgen deprivation therapy (ADT) with or without docetaxel (Doc): Long-term results of two phase 3 trials from the STAMPEDE platform protocol."Mr. Craig Jones answers the following questions: Could you distinguish osteoporotic from pathological fractures in your analysis based on routinely-collected healthcare data? Would a higher rate of pathological fractures explain the higher incidence of clinical fracture events in the M1 as compared to M0 subgroup?Are there data on symptomatic skeletal events as opposed to skeletal related events as a more relevant endpoint for health related quality of life?Risk of osteoporosis when utilising ADT+Docetaxel as compared to ADT+NHA?Denosumab outperformed Zoledronic acid for prevention of SRE in mCRPC. How would you compare both drugs in mHSPC? To keep up to date with prostate cancer developments, you can also visit our educational platform, UROONCO Prostate Cancer.

There are no comments yet.

Please log in to write the first comment.